Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use

Drug Resistance Updates

Volumn 9, Issue 1-2, 2006, Pages 26-39

  Pérez Victoria, F Javier ^a   Sánchez Cañete, María P ^a   Seifert, Karin ^b   Croft, Simon L ^c   Sundar, Shyam ^d   Castanys, Santiago ^a   Gamarro, Francisco ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Drugs for Neglected Diseases Initiative   (Switzerland)

^d BANARAS HINDU UNIVERSITY   (India)

Author keywords

Aminophospholipid translocase; CDC50 family; Control; Drug combinations; Experimental drug resistance; LdMT; LdRos3; Leishmania; Miltefosine

Indexed keywords

ABC TRANSPORTER; ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTINEOPLASTIC AGENT; ATOVAQUONE; CREATININE; DAUNORUBICIN; EDELFOSINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; ILMOFOSINE; IMMUNOSTIMULATING AGENT; KUTKIN; LDROS3 PROTEIN; LIVER ENZYME; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PHOSPHOLIPID DERIVATIVE; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; PYRROLE DERIVATIVE; RIFAMPICIN; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; BETA CHAIN; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG SAFETY; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENDEMIC DISEASE; GASTROINTESTINAL SYMPTOM; HEALTH CARE POLICY; HUMAN; INFECTION RISK; LEISHMANIA; LEISHMANIASIS; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTOZOAL INFECTION; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; SPECIES SPECIFICITY;

EID: 33745253122     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2006.04.001     Document Type: Article

References (80)

1. Anderson J.B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3 (2005) 547-556
2. Araujo-Santos J.M., Parodi-Talice A., Castanys S., and Gamarro F. The overexpression of an intracellular ABCA-like transporter alters phospholipid trafficking in Leishmania. Biochem. Biophys. Res. Commun. 330 (2005) 349-355
3. Arthur G., and Bittman R. The inhibition of cell signalling pathways by antitumor ether-lipids. Biochim. Biophys. Acta 1390 (1998) 85-102
4. Bhattacharya S.K., Jha T.K., Sundar S., Thakur C.P., Engel J., Sindermann H., Junge K., Karbwang J., Bryceson A.D., and Berman J.D. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. 38 (2004) 217-221
5. Beach D.H., Holz, and Anekwe G.E. Lipids of Leishmania promastigotes. J. Parasitol. 65 (1979) 201-216
6. Beach D.H., Goad L.J., and Holz G.G. Effects of antimytotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol. Biochem. Parasitol. 31 (1988) 149-162
7. Beckers T., Voegeli R., and Hilgard P. Molecular and cellular effects of hexadecylphosphocholine (miltefosine) in human myeloid leukaemia cell lines. Eur. J. Cancer 30A (1994) 2143-2150
8. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537-592
9. Brachwitz H., and Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharm. Ther. 66 (1995) 39-82
10. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6 (2001) 928-934
11. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., Klomp L.W., Lomri N., Berger R., Scharschmidt B.F., Knisely A.S., Houwen R.H., and Freimer N.B. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18 (1998) 219-224
12. Burk K., David M., Junge K., and Sindermann H. Overview on the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer. Drugs Today 30 (1994) 59-72
13. Callaghan R., van Gorkom L.C., and Epand R.M. A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br. J. Cancer 66 (1992) 781-786
14. Chunge C.N., Gachihi G., Muigai R., Wasunna K., Rashid J.R., Chulay J.D., Anabwani G., Oster C.N., and Bryceson A.D. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg. 79 (1985) 715-718
15. Chunge C.N., Owate J., Pamba H.O., and Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 221-225
16. Croft S.L. Drug Resistance in Leishmaniasis (2004), World Health Organization pp. 108-119
17. Croft S.L., Barrett M., and Urbina J.A. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol. 21 (2005) 508-512
18. Croft S.L., and Coombs G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19 (2003) 502-508
19. Croft S.L., Neal R.A., Pendergast W., and Chan J.H. The activity of alkylphosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36 (1987) 263-2636
20. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they?. J. Antimicrob. Chemother. 54 (2004) 854-869
21. Cupolillo E., Medina-Acosta E., Noyes H., Momen H., and Grimaldi Jr. G. A revised classification for Leishmania and Endotrypanum. Parasitol. Today 16 (2000) 142-144
22. Dube A., Singh N., and Sundar S. Refractoriness to the treament of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 96 (2005) 216-223
23. Ellard G.A. Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs. Int. J. Lepr. Other Mycobact. Dis. 52 (1984) 395-401
24. Escobar P., Matu S., Marques C., and Croft S.L. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81 (2002) 151-157
25. Gajate C., and Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab. 3 (2002) 491-525
26. Ganguly, N.K., 2002. Oral miltefosine may revolutionize treatment of visceral leishmaniasis. TDR News, World Health Organisation, vol. 68, p. 2.
27. Goad L., Holz G.G., and Beach D.H. Sterols of Leishmania species. Implication for biosynthesis. Mol. Biochem. Parasitol. 10 (1984) 161-170
28. Grant A.M., Hanson P.K., Malone L., and Nichols J.W. NBD-labeled phosphatidylcholine and phosphatidylethanolamine are internalized by transbilayer transport across the yeast plasma membrane. Traffic 2 (2001) 37-50
29. Grogl T., Thomason N., and Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47 (1992) 117-126
30. Gupta S., Ramesh S.C., and Srivastava V.M. Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Trop. 94 (2005) 47
31. Hanson P.K., Malone L., Birchmore J.L., and Nichols J.W. Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J. Biol. Chem. 278 (2003) 36041-36050
32. Hilgard P., Kampherm E., Nolan L., Pohl J., and Reissmann T. Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J. Cancer Res. Clin. Oncol. 117 (1991) 403-408
33. Hoffmann J., Utz I., Spitaler M., Hofe S., Rybczynska M., Beck W.T., Herrmann D.B., and Grunicke H. Resistance to the new anti-cancer phospholipid ilmofosine (BM41 440). Br. J. Cancer 76 (1997) 862-869
34. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., and Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341 (1999) 1795-1800
35. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., and Rex J.H. Combination antifungal therapy. Antimicrob. Agents Chemother. 48 (2004) 693-715
36. Kuhlencord A., Maniera T., Eibl H., and Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36 (1992) 1630-1634
37. Legare D., Richard D., Mukhopadhyay R., Stierhof Y.D., Rosen B.P., Haimeur A., Papadopoulou B., and Ouellette M. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 276 (2001) 26301-26307
38. Lira R., Contreras L.M., Rita R.M., and Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47 (2001) 537-546
39. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., and Sacks D. Evidence that the high incidente of treatment failures in Indian kala-azar is due to the emergente of antimony resistant strains of Leishmania donovani. J. Infect. Dis. 180 (1999) 564-567
40. Lux H., Heise N., Klenner T., Hart D., and Opperdoes F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111 (2000) 1-14
41. McConville M.J., Mullin K.A., Ilgoutz S.C., and Teasdale R.D. Secretory pathway of trypanosomatid parasites. Microbiol. Mol. Biol Rev. 66 (2002) 122-154
42. Murray H.W., and Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181 (2000) 795-799
43. Murray H.W., and Hariprashad J. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 40 (1996) 586-587
44. Neal R.A., Allen S., McCoy N., Olliaro P., and Croft S.L. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35 (1995) 577-584
45. Paris C., Loiseau P.M., Bories C., and Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 48 (2004) 852-859
46. Parodi-Talice A., Araujo J.M., Torres C., Pérez-Victoria J.M., Gamarro F., and Castanys S. The overexpression of a new ABC transporter in Leishmania is related to phospholipid trafficking and reduced infectivity. Biochim. Biophys. Acta 1612 2 (2003) 195-207
47. Pérez-Victoria F.J., Castanys S., and Gamarro F. Resistance to miltefosine in Leishmania donovani involves a defective inward translocation of the drug. Antimicrob. Agents Chemother. 47 (2003) 2397-2403
48. Pérez-Victoria F.J., Gamarro F., Ouellette M., and Castanys S. Functional cloning of the miltefosine transporter: a novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278 (2003) 49965-49971
49. Perez-Victoria J.M., Pérez-Victoria F.J., Parodi-Talice A., Jimenez I.A., Ravelo A.G., Castanys S., and Gamarro F. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45 (2001) 2468-2474
50. Pomorski T., Lombardi R., Riezman H., Devaux P.F., van Meer G., and Holthuis J.C. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol. Biol. Cell. 14 (2003) 1240-1254
51. Pomorski T., Holthuis J.C.M., Herrmann A., and van Meer G. Tracking down lipid flippases and their biological functions. J. Cell Sci. 117 (2004) 805-813
52. Quispe-Tintaya K.W., Laurent T., Decuypere S., Hide M., Banuls A.L., De Doncker S., Rijal S., Canavate C., Campino L., and Dujardin J.C. Fluorogenic assay for molecular typing of the Leishmania donovani complex: taxonomic and clinical applications. J. Infect. Dis. 192 (2005) 685-692
53. Raggers R.J., Pomorski T., Holthuis J.C., Kalin N., and van Meer G. Lipid traffic: the ABC of transbilayer movement. Traffic 1 (2000) 226-234
54. Rakotomanga M., Saint-Pierre-Chazalet M., and Loiseau P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 49 (2005) 2677-2686
55. Rybczynska M., Liu R., Lu P., Sharom F.J., Steinfels E., Pietro A.D., Spitaler M., Grunicke H., and Hofmann J. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer 84 (2001) 1405-1411
56. Rybczynska M., Spitaler M., Knebel N.G., Boeck G., Grunicke H., and Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 62 (2001) 765-772
57. Santa-Rita R.M., Santos Barbosa H., Meirelles M.N., and de Castro S.L. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 75 (2000) 219-228
58. Schraner C., Hasse B., Hasse U., Baumann D., Faeh A., Burg G., Grimm F., Mathis A., Weber R., and Gunthard H.F. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin. Infect. Dis. 40 (2005) 120-124
59. Seaman J., Pryce D., Sondorp H.E., Moody A., Bryceson A.D., and Davidson R.N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168 (1993) 715-720
60. Seifert K., Matu S., Pérez-Victoria F.J., Castanys S., Gamarro F., and Croft S.L. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 22 (2003) 380-387
61. Seifert K., and Croft S.L. In vitro and in vivo interactions between miltefosine and other anti-leishmanial drugs. Antimicrob. Agents Chemother. 50 (2006) 73-79
62. Sindermann H., Engel K.R., Fischer C., and Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 39 (2004) 1520-1523
63. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J., and Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38 (2004) 1266-1272
64. Soto J., Toledo J., Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., and Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33 (2001) 57-61
65. Storme G.A., Berdel W.E., van Blittterswijk W.J., Bruyneel E.A., De Bruyne G.K., and Marcel M.M. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methlglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Cancer Res. 45 (1985) 351-357
66. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6 (2001) 654-849
67. Sundar S., Jha T.K., Sindermann H., Junge K., Bachmann P., and Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J. 22 (2003) 434-438
68. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Klaus K., Anthony Bryceson A., and Berman J. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347 (2002) 1739-1746
69. Sundar S., Makharia A., More D.K., Agrawal G., Voss A., Fischer C., Bachmann P., and Murray H.W. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31 (2000) 1110-1113
70. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., Kumar P.C., and Murray H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31 (2000) 1104-1107
71. Sundar S., and Murray H.W. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ. 83 (2005) 394-395
72. Tang X., Halleck M.S., Schlegel R.A., and Williamson P. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science 272 (1996) 1495-1497
73. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Zaniewski A.E., Houlihan H.H., and Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94 (2000) 429-431
74. van der Sanden M.H., Houweling M., Duijsings D., Vaandrager A.B., and van Golde L.M. Inhibition of phosphatidycholine sinthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim. Biophys. Acta 1636 (2004) 99-107
75. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., and van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 (1996) 507-517
76. Verma N.K., and Dey C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. 48 (2004) 3010-3015
77. White N.J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41 (1999) 301-308
78. Yardley V., Croft S.L., De Doncker S., Dujardin J.C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., and Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73 (2005) 272-275
79. Zeisig R., Rudolf M., Eue I., and Arndt D. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 121 (1995) 69-75
80. Zoeller R.A., Layne M.D., and Modest E.J. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 36 (1995) 1866-1875